Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade.

Rashidian M, LaFleur MW, Verschoor VL, Dongre A, Zhang Y, Nguyen TH, Kolifrath S, Aref AR, Lau CJ, Paweletz CP, Bu X, Freeman GJ, Barrasa MI, Weinberg RA, Sharpe AH, Ploegh HL.

Proc Natl Acad Sci U S A. 2019 Aug 20;116(34):16971-16980. doi: 10.1073/pnas.1905005116. Epub 2019 Aug 2.

PMID:
31375632
2.

Generation of Induced Pluripotent Cancer Cells from Glioblastoma Multiform Cell Lines.

Vatanmakanian M, Yousefi H, Mashouri L, Aref AR, Khamisipour G, Bitaraf A, Alizadeh S.

Cell Reprogram. 2019 Aug 1. doi: 10.1089/cell.2019.0046. [Epub ahead of print]

PMID:
31369321
3.

Microfluidic Brain-on-a-Chip: Perspectives for Mimicking Neural System Disorders.

Mofazzal Jahromi MA, Abdoli A, Rahmanian M, Bardania H, Bayandori M, Moosavi Basri SM, Kalbasi A, Aref AR, Karimi M, Hamblin MR.

Mol Neurobiol. 2019 Jul 1. doi: 10.1007/s12035-019-01653-2. [Epub ahead of print] Review.

PMID:
31264092
4.

Aggregate Forms of Recombinant Human Erythropoietin With Different Charge Profile Substantially Impact Biological Activities.

Ghezlou M, Mokhtari F, Kalbasi A, Riazi G, Kaghazian H, Emadi R, Aref AR.

J Pharm Sci. 2019 Jun 16. pii: S0022-3549(19)30375-2. doi: 10.1016/j.xphs.2019.05.036. [Epub ahead of print]

PMID:
31216452
5.

Personalized medicine in breast cancer: pharmacogenomics approaches.

Jeibouei S, Akbari ME, Kalbasi A, Aref AR, Ajoudanian M, Rezvani A, Zali H.

Pharmgenomics Pers Med. 2019 May 27;12:59-73. doi: 10.2147/PGPM.S167886. eCollection 2019. Review.

6.

Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance.

Mashouri L, Yousefi H, Aref AR, Ahadi AM, Molaei F, Alahari SK.

Mol Cancer. 2019 Apr 2;18(1):75. doi: 10.1186/s12943-019-0991-5. Review.

7.

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N.

Cell. 2019 Jan 10;176(1-2):404. doi: 10.1016/j.cell.2018.12.034. No abstract available.

8.

Photoluminescent functionalized carbon dots for CRISPR delivery: synthesis, optimization and cellular investigation.

Hasanzadeh A, Radmanesh F, Kiani J, Bayandori M, Fatahi Y, Aref AR, Karimi M.

Nanotechnology. 2019 Mar 29;30(13):135101. doi: 10.1088/1361-6528/aafbf9. Epub 2019 Jan 4.

PMID:
30609415
9.

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N.

Cell. 2018 Nov 1;175(4):998-1013.e20. doi: 10.1016/j.cell.2018.10.038. Erratum in: Cell. 2019 Jan 10;176(1-2):404.

PMID:
30388456
10.

3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade.

Aref AR, Campisi M, Ivanova E, Portell A, Larios D, Piel BP, Mathur N, Zhou C, Coakley RV, Bartels A, Bowden M, Herbert Z, Hill S, Gilhooley S, Carter J, Cañadas I, Thai TC, Kitajima S, Chiono V, Paweletz CP, Barbie DA, Kamm RD, Jenkins RW.

Lab Chip. 2018 Oct 9;18(20):3129-3143. doi: 10.1039/c8lc00322j.

PMID:
30183789
11.

Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses.

Cañadas I, Thummalapalli R, Kim JW, Kitajima S, Jenkins RW, Christensen CL, Campisi M, Kuang Y, Zhang Y, Gjini E, Zhang G, Tian T, Sen DR, Miao D, Imamura Y, Thai T, Piel B, Terai H, Aref AR, Hagan T, Koyama S, Watanabe M, Baba H, Adeni AE, Lydon CA, Tamayo P, Wei Z, Herlyn M, Barbie TU, Uppaluri R, Sholl LM, Sicinska E, Sands J, Rodig S, Wong KK, Paweletz CP, Watanabe H, Barbie DA.

Nat Med. 2018 Aug;24(8):1143-1150. doi: 10.1038/s41591-018-0116-5. Epub 2018 Jul 23.

12.

Optical assays based on colloidal inorganic nanoparticles.

Ghasemi A, Rabiee N, Ahmadi S, Hashemzadeh S, Lolasi F, Bozorgomid M, Kalbasi A, Nasseri B, Shiralizadeh Dezfuli A, Aref AR, Karimi M, Hamblin MR.

Analyst. 2018 Jul 21;143(14):3249-3283. doi: 10.1039/c8an00731d. Epub 2018 Jun 20. Review.

13.

Integrated use of bioinformatic resources reveals that co-targeting of histone deacetylases, IKBK and SRC inhibits epithelial-mesenchymal transition in cancer.

Barneh F, Mirzaie M, Nickchi P, Tan TZ, Thiery JP, Piran M, Salimi M, Goshadrou F, Aref AR, Jafari M.

Brief Bioinform. 2019 Mar 25;20(2):717-731. doi: 10.1093/bib/bby030.

PMID:
29726962
14.

Personalized Cancer Medicine: An Organoid Approach.

Aboulkheyr Es H, Montazeri L, Aref AR, Vosough M, Baharvand H.

Trends Biotechnol. 2018 Apr;36(4):358-371. doi: 10.1016/j.tibtech.2017.12.005. Epub 2018 Jan 20. Review.

PMID:
29366522
15.

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.

Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, Ivanova E, Paweletz CP, Bowden M, Zhou CW, Herter-Sprie GS, Sorrentino JA, Bisi JE, Lizotte PH, Merlino AA, Quinn MM, Bufe LE, Yang A, Zhang Y, Zhang H, Gao P, Chen T, Cavanaugh ME, Rode AJ, Haines E, Roberts PJ, Strum JC, Richards WG, Lorch JH, Parangi S, Gunda V, Boland GM, Bueno R, Palakurthi S, Freeman GJ, Ritz J, Haining WN, Sharpless NE, Arthanari H, Shapiro GI, Barbie DA, Gray NS, Wong KK.

Cancer Discov. 2018 Feb;8(2):216-233. doi: 10.1158/2159-8290.CD-17-0915. Epub 2017 Nov 3.

16.

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, Wei Z, Palakurthi S, Bittinger M, Vitzthum H, Kim JW, Merlino A, Quinn M, Venkataramani C, Kaplan JA, Portell A, Gokhale PC, Phillips B, Smart A, Rotem A, Jones RE, Keogh L, Anguiano M, Stapleton L, Jia Z, Barzily-Rokni M, Cañadas I, Thai TC, Hammond MR, Vlahos R, Wang ES, Zhang H, Li S, Hanna GJ, Huang W, Hoang MP, Piris A, Eliane JP, Stemmer-Rachamimov AO, Cameron L, Su MJ, Shah P, Izar B, Thakuria M, LeBoeuf NR, Rabinowits G, Gunda V, Parangi S, Cleary JM, Miller BC, Kitajima S, Thummalapalli R, Miao B, Barbie TU, Sivathanu V, Wong J, Richards WG, Bueno R, Yoon CH, Miret J, Herlyn M, Garraway LA, Van Allen EM, Freeman GJ, Kirschmeier PT, Lorch JH, Ott PA, Hodi FS, Flaherty KT, Kamm RD, Boland GM, Wong KK, Dornan D, Paweletz CP, Barbie DA.

Cancer Discov. 2018 Feb;8(2):196-215. doi: 10.1158/2159-8290.CD-17-0833. Epub 2017 Nov 3.

17.

Carbon nanotubes in microfluidic lab-on-a-chip technology: current trends and future perspectives.

Ghasemi A, Amiri H, Zare H, Masroor M, Hasanzadeh A, Beyzavi A, Aref AR, Karimi M, Hamblin MR.

Microfluid Nanofluidics. 2017 Sep;21(9). pii: 151. doi: 10.1007/s10404-017-1989-1. Epub 2017 Sep 5.

18.

Nanomedicine and advanced technologies for burns: Preventing infection and facilitating wound healing.

Mofazzal Jahromi MA, Sahandi Zangabad P, Moosavi Basri SM, Sahandi Zangabad K, Ghamarypour A, Aref AR, Karimi M, Hamblin MR.

Adv Drug Deliv Rev. 2018 Jan 1;123:33-64. doi: 10.1016/j.addr.2017.08.001. Epub 2017 Aug 4. Review.

19.

Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.

Adeegbe DO, Liu Y, Lizotte PH, Kamihara Y, Aref AR, Almonte C, Dries R, Li Y, Liu S, Wang X, Warner-Hatten T, Castrillon J, Yuan GC, Poudel-Neupane N, Zhang H, Guerriero JL, Han S, Awad MM, Barbie DA, Ritz J, Jones SS, Hammerman PS, Bradner J, Quayle SN, Wong KK.

Cancer Discov. 2017 Aug;7(8):852-867. doi: 10.1158/2159-8290.CD-16-1020. Epub 2017 Apr 13.

20.

Microfluidic systems for stem cell-based neural tissue engineering.

Karimi M, Bahrami S, Mirshekari H, Basri SM, Nik AB, Aref AR, Akbari M, Hamblin MR.

Lab Chip. 2016 Jul 5;16(14):2551-71. doi: 10.1039/c6lc00489j. Review.

21.

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.

Koyama S, Akbay EA, Li YY, Aref AR, Skoulidis F, Herter-Sprie GS, Buczkowski KA, Liu Y, Awad MM, Denning WL, Diao L, Wang J, Parra-Cuentas ER, Wistuba II, Soucheray M, Thai T, Asahina H, Kitajima S, Altabef A, Cavanaugh JD, Rhee K, Gao P, Zhang H, Fecci PE, Shimamura T, Hellmann MD, Heymach JV, Hodi FS, Freeman GJ, Barbie DA, Dranoff G, Hammerman PS, Wong KK.

Cancer Res. 2016 Mar 1;76(5):999-1008. doi: 10.1158/0008-5472.CAN-15-1439. Epub 2016 Feb 1.

22.

Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems.

Karimi M, Ghasemi A, Sahandi Zangabad P, Rahighi R, Moosavi Basri SM, Mirshekari H, Amiri M, Shafaei Pishabad Z, Aslani A, Bozorgomid M, Ghosh D, Beyzavi A, Vaseghi A, Aref AR, Haghani L, Bahrami S, Hamblin MR.

Chem Soc Rev. 2016 Mar 7;45(5):1457-501. doi: 10.1039/c5cs00798d. Review.

23.

Nanolayered tin phosphate: a remarkably selective Cs ion sieve for acidic waste solutions.

Huang W, Komarneni S, Aref AR, Noh YD, Ma J, Chen K, Xue D, Jiang B.

Chem Commun (Camb). 2015 Nov 7;51(86):15661-4. doi: 10.1039/c5cc06560g. Epub 2015 Sep 11.

PMID:
26359760
24.

Carbon nanotubes part II: a remarkable carrier for drug and gene delivery.

Karimi M, Solati N, Ghasemi A, Estiar MA, Hashemkhani M, Kiani P, Mohamed E, Saeidi A, Taheri M, Avci P, Aref AR, Amiri M, Baniasadi F, Hamblin MR.

Expert Opin Drug Deliv. 2015 Jul;12(7):1089-105. doi: 10.1517/17425247.2015.1004309. Epub 2015 Jan 22. Review.

25.

Carbon nanotubes part I: preparation of a novel and versatile drug-delivery vehicle.

Karimi M, Solati N, Amiri M, Mirshekari H, Mohamed E, Taheri M, Hashemkhani M, Saeidi A, Estiar MA, Kiani P, Ghasemi A, Basri SM, Aref AR, Hamblin MR.

Expert Opin Drug Deliv. 2015 Jul;12(7):1071-87. doi: 10.1517/17425247.2015.1003806. Epub 2015 Jan 19. Review.

26.

Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor.

Christensen CL, Kwiatkowski N, Abraham BJ, Carretero J, Al-Shahrour F, Zhang T, Chipumuro E, Herter-Sprie GS, Akbay EA, Altabef A, Zhang J, Shimamura T, Capelletti M, Reibel JB, Cavanaugh JD, Gao P, Liu Y, Michaelsen SR, Poulsen HS, Aref AR, Barbie DA, Bradner JE, George RE, Gray NS, Young RA, Wong KK.

Cancer Cell. 2014 Dec 8;26(6):909-922. doi: 10.1016/j.ccell.2014.10.019. Erratum in: Cancer Cell. 2015 Jan 12;27(1):149.

27.

Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth.

Barbie TU, Alexe G, Aref AR, Li S, Zhu Z, Zhang X, Imamura Y, Thai TC, Huang Y, Bowden M, Herndon J, Cohoon TJ, Fleming T, Tamayo P, Mesirov JP, Ogino S, Wong KK, Ellis MJ, Hahn WC, Barbie DA, Gillanders WE.

J Clin Invest. 2014 Dec;124(12):5411-23. doi: 10.1172/JCI75661. Epub 2014 Nov 3.

28.

Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.

Tan L, Wang J, Tanizaki J, Huang Z, Aref AR, Rusan M, Zhu SJ, Zhang Y, Ercan D, Liao RG, Capelletti M, Zhou W, Hur W, Kim N, Sim T, Gaudet S, Barbie DA, Yeh JR, Yun CH, Hammerman PS, Mohammadi M, Jänne PA, Gray NS.

Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):E4869-77. doi: 10.1073/pnas.1403438111. Epub 2014 Oct 27.

29.

Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit.

Zhu Z, Aref AR, Cohoon TJ, Barbie TU, Imamura Y, Yang S, Moody SE, Shen RR, Schinzel AC, Thai TC, Reibel JB, Tamayo P, Godfrey JT, Qian ZR, Page AN, Maciag K, Chan EM, Silkworth W, Labowsky MT, Rozhansky L, Mesirov JP, Gillanders WE, Ogino S, Hacohen N, Gaudet S, Eck MJ, Engelman JA, Corcoran RB, Wong KK, Hahn WC, Barbie DA.

Cancer Discov. 2014 Apr;4(4):452-65. doi: 10.1158/2159-8290.CD-13-0646. Epub 2014 Jan 20.

30.

Complementary effects of ciclopirox olamine, a prolyl hydroxylase inhibitor and sphingosine 1-phosphate on fibroblasts and endothelial cells in driving capillary sprouting.

Lim SH, Kim C, Aref AR, Kamm RD, Raghunath M.

Integr Biol (Camb). 2013 Dec;5(12):1474-84. doi: 10.1039/c3ib40082d.

PMID:
24190477
31.

Screening therapeutic EMT blocking agents in a three-dimensional microenvironment.

Aref AR, Huang RY, Yu W, Chua KN, Sun W, Tu TY, Bai J, Sim WJ, Zervantonakis IK, Thiery JP, Kamm RD.

Integr Biol (Camb). 2013 Feb;5(2):381-9. doi: 10.1039/c2ib20209c.

Supplemental Content

Support Center